ANI Pharmaceuticals: 2,528 restricted shares proposed sale; Matthew Leonard sold 6,937 shares

Rhea-AI Filing Summary

ANI Pharmaceuticals (ANIP) Form 144 notice shows a proposed sale of 2,528 restricted common shares by or for an identified person through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $229,075.98 and an approximate sale date of 08/25/2025. The filing states those shares were acquired as restricted stock from the issuer on 08/21/2025 and paid for on that date. The form also discloses a separate sale by Matthew Leonard of 6,937 common shares on 08/18/2025 with gross proceeds of $611,644.31. The filer certifies they have no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine Rule 144 sale notice disclosing a small restricted-stock sale and a recent larger sale by Matthew Leonard.

The filing records a proposed sale of 2,528 restricted shares valued at $229,075.98 and a prior sale of 6,937 shares generating $611,644.31. For investors, this is a transfer disclosure rather than an operational update; it provides transparency about insider liquidity but contains no financial results or forecasts. No new material company information is presented beyond the transactions and timing.

Compliance Counsel

TL;DR: Form 144 appears properly completed and includes required acquisition, sale and broker details.

The form specifies acquisition dates, nature of acquisition (restricted stock), broker identity, sale amounts, aggregate market value, and the seller's representation about material information. These elements align with Rule 144 disclosure requirements. The filing does not include any statements suggesting noncompliance or undisclosed material events; it is a routine compliance disclosure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2528	229075.98	21688772	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/21/2025	Restricted Stock	Issuer			2528	08/21/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MATTHEW LEONARD 210 Main Street West Baudette MN 56623	Common	08/18/2025	6937	611644.31

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ANIP Form 144 disclose about proposed sales?

The filing discloses a proposed sale of 2,528 restricted common shares valued at $229,075.98 through Morgan Stanley Smith Barney on 08/25/2025.

Who sold shares recently according to the filing for ANIP?

Matthew Leonard sold 6,937 common shares on 08/18/2025 for gross proceeds of $611,644.31.

When were the 2,528 shares acquired and what type were they?

The 2,528 shares were acquired on 08/21/2025 as restricted stock from the issuer, with payment recorded on the same date.

Which broker is handling the proposed sale in the ANIP Form 144?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filing state any undisclosed material information about ANIP?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.